The landscape of global oncology is shifting as Chinese biotechnology firms transition from fast-followers to industry pioneers. At the recent European Lung Cancer Congress in Copenhagen, Sichuan-based Bioken (Baili-Tianheng) unveiled Phase II clinical data for its bispecific antibody-drug conjugate, iza-bren, in treating extensive-stage small cell lung cancer. The results represent a significant departure from current clinical plateaus, offering a glimpse into a future where Chinese-originated molecules define global standards of care.
Led by Professor Zhou Caicun of Shanghai’s East Hospital, the study evaluated iza-bren in combination with a PD-1 inhibitor as a first-line treatment. The findings were startling: a median progression-free survival of 8.2 months and a one-year overall survival rate of 85.7%. Most remarkably, every patient in the trial experienced some degree of tumor shrinkage in target lesions, a 100% response rate that has largely eluded traditional chemotherapy-immunotherapy combinations.
This clinical success follows a landmark $8.4 billion global strategic partnership between Bioken and Bristol Myers Squibb signed in late 2023. That deal, which marked the first time a Chinese-developed bispecific ADC achieved a multi-billion dollar international license, signaled Wall Street’s growing confidence in China’s innovative capacity. By leveraging Chinese clinical data for global development, the partnership exemplifies the 'in China for global' model that is increasingly prevalent in the pharmaceutical sector.
The broader implications for China’s industrial policy are equally profound. National Medical Products Administration data reveals that innovative drug out-licensing deals exceeded $60 billion in the first quarter of 2026 alone, nearly half of the previous year’s record total. This surge underscores a fundamental transformation in China’s domestic pharmaceutical ecosystem, driven by a strategic pivot away from generic manufacturing toward high-value, original biotherapeutic research.
Bioken’s aggressive expansion, including a 2-billion-yuan production base in Chengdu and a new '0-to-1' innovation center in Shanghai’s Pudong district, reflects a long-term commitment to maintaining this momentum. With 17 innovative drugs currently in clinical trials and six launching globally, the firm is positioning itself to compete directly with established pharmaceutical giants. This trajectory suggests that the '15th Five-Year Plan' period will likely be defined by China’s emergence as a dominant force in the global $200 billion oncology market.